戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ome of menopause can be treated with vaginal estrogen therapy.
2 acute abdominal pain after starting low-dose estrogen therapy.
3  identifying patients likely to benefit from estrogen therapy.
4 er contribute to acquired resistance to anti-estrogen therapy.
5  in the development of insensitivity to anti-estrogen therapy.
6 st cancer patients who are resistant to anti-estrogen therapy.
7 breast cancer regression resulting from anti-estrogen therapy.
8  breast cancer risk than is use of unopposed estrogen therapy.
9  BMD changes were independent of concomitant estrogen therapy.
10  Symptoms Scale subscale comparisons favored estrogen therapy.
11 ty was reduced to 46% (p < 0.01) in women on estrogen therapy.
12 gnaling, tumor growth and its effect on anti-estrogen therapy.
13  and benefits associated with postmenopausal estrogen therapy.
14 ether its effects exceed those expected with estrogen therapy.
15  partially explain the beneficial effects of estrogen therapy.
16 t may be related to adverse early effects of estrogen therapy.
17 e cardioprotective effects of postmenopausal estrogen therapy.
18 rough PRL/PAK1 may impart resistance to anti-estrogen therapies.
19 refore, there is a need for developing safer estrogen therapies.
20 tient-year in women with VTE associated with estrogen therapy (0 of 58) (P = 0.001 for the 3-group co
21 d, double-blind, placebo-controlled trial of estrogen therapy (1 mg of estradiol-17beta per day) in 6
22 t-year in women with VTE not associated with estrogen therapy (9 of 81), and 0.0% (CI, 0.0% to 3.0%)
23  Multivariable analysis identified diabetes, estrogen therapy (adjusted risk ratio 0.38, 95% confiden
24 e presence of an association did not vary by estrogen therapy after bilateral oophorectomy, with asso
25  of patients with breast cancer used vaginal estrogen therapy after breast cancer diagnosis.
26 ausal women, age at oophorectomy, and use of estrogen therapy after oophorectomy with cognitive perfo
27                                              Estrogen therapy alone did not reduce dementia or MCI in
28  investigations was to assess the effects of estrogen therapy alone or with progesterone on executive
29 ast cancer risk substantially more than does estrogen therapy alone.
30 the authors examined the association between estrogen therapy and bone mineral density in older Afric
31         We examined the relationship between estrogen therapy and coronary-artery calcium in the cont
32 elling evidence of cardiovascular benefit of estrogen therapy and estrogen and progestin therapy in o
33 ssessed thyroid function before they started estrogen therapy and every 6 weeks for 48 weeks thereaft
34  demonstrated during pregnancy and high dose estrogen therapy and is thought to be the primary mechan
35 ion compared to daily cranberry pills, daily estrogen therapy, and acupuncture.
36 tia are decreased in women who have received estrogen therapy, and betaE2 protects neurons in vitro a
37                New trials of lipid lowering, estrogen therapy, and hypertension control have added to
38 epression may benefit from short-term use of estrogen therapy, and its role for postmenopausal depres
39 surgery, the potential risks and benefits of estrogen therapy, and the role of the primary care pract
40 .56; 95% CI, 1.24-5.31; P = .01) and without estrogen therapy (aOR, 2.05; 95% CI, 1.18-3.52; P = .01)
41 ons among women aged less than 46 years with estrogen therapy (aOR, 2.56; 95% CI, 1.24-5.31; P = .01)
42                                        Thus, estrogen therapy appears to have unique properties that
43                                         Anti-estrogen therapies are available to prevent postmenopaus
44  ovarian function remains intact, these anti-estrogen therapies are not as effective.
45                  These beneficial effects of estrogen therapy are highly modified by apolipoprotein E
46  brain and memory of this short-term midlife estrogen therapy are unclear.
47 of 137 consecutive women receiving long-term estrogen therapy at the time of elective PTCA and during
48   The active regimens were conjugated equine estrogens therapy at 0.625 mg daily, alone or in combina
49  current recommendations are that menopausal estrogen therapy be limited to a few years.
50 erated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate
51 l concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholester
52 oxine-binding globulin concentrations during estrogen therapy, but their serum free thyroxine concent
53 pport the guidelines suggesting that vaginal estrogen therapy can be considered in patients with brea
54                                              Estrogen therapy can have unpleasant gynecologic and non
55                                              Estrogen therapy can promote cognitive function if initi
56 cific mortality in patients who used vaginal estrogen therapy compared with patients who did not use
57 t in Th1/Th2 balance suggested that low dose estrogen therapy could bias the immune reaction toward a
58                                              Estrogen therapy did not change systolic pressure (128+/
59                                              Estrogen therapy did not reduce the risk of death alone
60        Whether health outcomes of menopausal estrogen therapy differ between women with and without b
61 e antibiotics for 6 to 12 months and vaginal estrogen therapy effectively reduce symptomatic UTI epis
62  to reevaluate the circumstances under which estrogen therapy (ET) provides benefits against cerebral
63  women who were randomly assigned to receive estrogen therapy had a higher risk of fatal stroke (rela
64 ith never users, women taking unopposed oral estrogen therapy had increased risks of both serous tumo
65                                   The use of estrogen therapy has declined sharply after the Women's
66               These results demonstrate that estrogen therapy has no effect on infarction volume foll
67                                However, anti-estrogen therapy has not been shown to be effective in e
68 orial trials of PFKFB3 antagonists with anti-estrogen therapies in ER(+) stage IV breast cancer patie
69 ctivity and continued responsiveness to anti-estrogen therapies in vitro.
70 he understanding of the role of estrogen and estrogen therapy in bladder health and pathogen defense
71 ussed with respect to therapeutic targets of estrogen therapy in brain.
72 igated the efficacy and safety of short-term estrogen therapy in decreasing noncognitive signs and sy
73                   Investigation of high dose estrogen therapy in in vivo models of CNS hemorrhage, tr
74 ere are concerns about the safety of vaginal estrogen therapy in patients with breast cancer.
75                                              Estrogen therapy in postmenopausal women has been associ
76  interest as potential alternatives to using estrogen therapy in treating menopausal symptoms.
77                               Four trials of estrogen therapy in women with Alzheimer disease have be
78                   Important new data on anti-estrogen therapy, including aromatase inhibitors and pur
79                               Use of vaginal estrogen therapy, including vaginal tablets and creams,
80 t, in carriers of apolipoprotein E4 (ApoE4), estrogen therapy increased the risk of late-onset Alzhei
81 tcome following adjuvant treatment with anti-estrogen therapy, independently of age, tumor grade, and
82                                              Estrogen therapy is effective in treating patients with
83                                              Estrogen therapy is known to prevent osteoporosis, but s
84 to the potential risks of long-term systemic estrogen therapy, many menopausal women are interested i
85                    Moreover, topical vaginal estrogen therapy may be an effective means of reducing H
86       Antidepressant benefit associated with estrogen therapy may be independent of improvement in ph
87 -like neuropathology in vivo Brain-selective estrogen therapy may be useful in delaying or reducing P
88  with hypothyroidism treated with thyroxine, estrogen therapy may increase the need for thyroxine.
89 ese preliminary data suggest that short-term estrogen therapy may safely decrease the frequency and s
90  Relative to monkeys receiving either of the estrogen therapies, monkeys receiving placebo were impai
91 f Opportunity' hypothesis, which states that estrogen therapy must be administered within a limited p
92 eimer disease, but studies of the effects of estrogen therapy on Alzheimer disease have been inconsis
93                                   Effects of estrogen therapy on cognitive performance are due, at le
94                        Beneficial effects of estrogen therapy on cognitive performance diminish with
95 rs examined the effect of a 4-week course of estrogen therapy on depression in perimenopausal and pos
96 r XIII genotypes and their interactions with estrogen therapy on risk of nonfatal myocardial infarcti
97 rs either does not initially respond to anti-estrogen therapy or develops resistance to such treatmen
98 n 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen
99 polymorphisms in determining the response to estrogen therapy or the risk of clinical cardiovascular
100 en receptor (ER(+)) and is treated with anti-estrogen therapies, particularly tamoxifen in premenopau
101         Epidemiological studies suggest that estrogen therapy protects against clinical expression of
102 D), whereas in individuals carrying ApoE2/3, estrogen therapy reduced the risk of AD.
103 and recent data indicate that postmenopausal estrogen therapy reduces the incidence of CHD by > 40%.
104                Despite the known efficacy of estrogen therapy, the lack of a predictive biomarker of
105                               Treatment with estrogen therapy through the age of 46 years in women wh
106  for the development and application of anti-estrogen therapies to treat cancer in premenopausal wome
107                                   The use of estrogen therapy to prevent cardiovascular disease in po
108            Later age at menopause, unopposed estrogen therapy use, and obesity were associated with i
109                                   In vaginal estrogen therapy users compared with HRT nonusers, there
110 cancer-specific mortality, comparing vaginal estrogen therapy users with HRT nonusers and adjusting f
111                                              Estrogen therapy was associated with a significantly gre
112                                    Unopposed estrogen therapy was associated with the Raynaud phenome
113                          High-dose synthetic estrogen therapy was the standard treatment of advanced
114 g prevalence, predictors, and treatment with estrogen therapy, was reviewed.
115                     Given the known risks of estrogen therapy, we do not recommend estrogen for the p
116 evices, injectable bulking agents, and local estrogen therapy were inconsistent.
117                                              Estrogen therapy, which has been shown to increase NO bi
118 omly assigned to usual care (control group), estrogen therapy with micronized 17beta-estradiol alone
119       Clinical trial evidence indicates that estrogen therapy with or without progestins increases ve
120                               Postmenopausal estrogen therapy, with or without concomitant progestin

 
Page Top